Latest news with #ConsensusEstimate
Yahoo
a day ago
- Business
- Yahoo
Why Is Progressive (PGR) Up 1.5% Since Last Earnings Report?
It has been about a month since the last earnings report for Progressive (PGR). Shares have added about 1.5% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Progressive due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important drivers. Progressive's Q2 Earnings and Revenues Beat on Higher PremiumsThe Progressive Corporation's second-quarter 2025 earnings per share of $4.88 beat the Zacks Consensus Estimate by 10.1%. The bottom line increased 84.1% year over year. Behind the Headlines Net premiums written were $20 billion in the quarter, up 12% from $17.9 billion a year ago. Net premiums earned grew 18% to $20.3 billion. The reported figure surpassed the Zacks Consensus Estimate of $20.1 billion. Operating revenues increased 19.5% year over year to $42.2 billion, driven by 19% higher net premiums earned, a 29.3% increase in net investment income, an 18.9% rise in fees and 28% higher service revenues. The top line beat the Zacks Consensus Estimate by 96.4%.Total expenses increased 15.1% to $35.2 billion, attributable to 12% higher losses and loss adjustment expenses, a 17% increase in policy acquisition costs, a 31.5% surge in other underwriting expenses, and a 23.6% rise in service realized gain on securities was $387 million versus a loss of $127 million in the year-ago quarter. Combined ratio — the percentage of premiums paid out as claims and expenses — improved 570 basis points (bps) from the prior-year quarter's level to 86.2. June Policies in Force Policies in force were solid in the Personal Lines segment, increasing 16% from the year-ago month's figure to 36.1 million. Special Lines improved 9% to 6.8 million. In the Personal Auto segment, Agency Auto increased 16% year over year to 10.4 million, while Direct Auto jumped 21% to 15.2 Commercial Auto segment policies rose 6% year over year to 1.2 million. The Property business had 3.6 million policies in force, up 8%. Financial Update Progressive's book value per share was $55.62 as of June 30, 2025, up 39.5% from $39.85 as of June 30, 2024. Return on equity in June 2025 was 43.6%, up from 40.2% reported in the year-ago period. The total debt-to-total capital ratio improved 530 bps to 17.5. How Have Estimates Been Moving Since Then? In the past month, investors have witnessed a upward trend in fresh estimates. VGM Scores At this time, Progressive has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. However, the stock has a grade of B on the value side, putting it in the top 40% for value investors. Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in. Outlook Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Progressive has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Progressive Corporation (PGR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Business
- Yahoo
P3 Health Partners Inc. (PIII) Reports Q2 Loss, Lags Revenue Estimates
P3 Health Partners Inc. (PIII) came out with a quarterly loss of $6.23 per share versus the Zacks Consensus Estimate of a loss of $3.29. This compares to a loss of $7.5 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -89.36%. A quarter ago, it was expected that this company would post a loss of $5 per share when it actually produced a loss of $6.28, delivering a surprise of -25.6%. Over the last four quarters, the company has not been able to surpass consensus EPS estimates. P3 Health Partners , which belongs to the Zacks Medical Info Systems industry, posted revenues of $355.79 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 2.03%. This compares to year-ago revenues of $379.16 million. The company has topped consensus revenue estimates just once over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. P3 Health Partners shares have lost about 36.9% since the beginning of the year versus the S&P 500's gain of 10%. What's Next for P3 Health Partners ? While P3 Health Partners has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for P3 Health Partners was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$5.04 on $342.9 million in revenues for the coming quarter and -$16.60 on $1.43 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Info Systems is currently in the top 36% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Phreesia (PHR), another stock in the same industry, has yet to report results for the quarter ended July 2025. The results are expected to be released on September 4. This developer of health care software is expected to post quarterly loss of $0.07 per share in its upcoming report, which represents a year-over-year change of +77.4%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Phreesia's revenues are expected to be $116.45 million, up 14% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report P3 Health Partners Inc. (PIII) : Free Stock Analysis Report Phreesia, Inc. (PHR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
2 days ago
- Business
- Yahoo
IGC Pharma, Inc. (IGC) Reports Q1 Loss, Misses Revenue Estimates
IGC Pharma, Inc. (IGC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +33.33%. A quarter ago, it was expected that this company would post a loss of $0.02 per share when it actually produced a loss of $0.01, delivering a surprise of +50%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. IGC Pharma, Inc., which belongs to the Zacks Medical - Drugs industry, posted revenues of $0.33 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 0.61%. This compares to year-ago revenues of $0.27 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. IGC Pharma, Inc. shares have added about 5.7% since the beginning of the year versus the S&P 500's gain of 10%. What's Next for IGC Pharma, Inc.? While IGC Pharma, Inc. has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for IGC Pharma, Inc. was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.03 on $0.49 million in revenues for the coming quarter and -$0.11 on $1.5 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the broader Zacks Medical sector, Premier, Inc. (PINC), has yet to report results for the quarter ended June 2025. The results are expected to be released on August 19. This company is expected to post quarterly earnings of $0.34 per share in its upcoming report, which represents a year-over-year change of -50.7%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Premier, Inc.'s revenues are expected to be $242.42 million, down 30.8% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report IGC Pharma, Inc. (IGC) : Free Stock Analysis Report Premier, Inc. (PINC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
Salesforce Pushes Data Cloud Adoption: Will It Anchor Growth?
Salesforce, Inc. CRM is making its Data Cloud platform a key part of its growth strategy. Data Cloud platform brings together customer data from multiple sources and makes it usable across Salesforce products. In the last reported financial results for the first quarter of fiscal 2026, the platform's annual recurring revenues soared 120% year over year and stored more than 22 trillion data points. Salesforce is witnessing a strong adoption trend for its Data Cloud platform. In the first quarter, nearly 60% of the company's top 100 deals included both Data Cloud and artificial intelligence (AI) capabilities, reflecting how valuable they can be if paired together. Additionally, roughly half of the new Data Cloud bookings in the last reported quarter came from existing clients, suggesting strong satisfaction and room for further growth. Salesforce is also integrating the Data Cloud platform with its other tools like Agentforce, Tableau and Slack. These connections make it easier for enterprises to activate their data and apply AI across operations. This integration could drive higher contract values and deeper customer relationships for Salesforce. To stay ahead in the competition across the enterprise software space, Salesforce will need to continuously upgrade its products and ensure quick, cost-effective deployment for clients. If the company can continue this momentum, Data Cloud could serve as a major revenue driver and strengthen Salesforce's position in AI-powered enterprise solutions. We believe that the Data Cloud platform has the potential to anchor Salesforce's revenues, which are currently witnessing a decelerating growth trend. After years of consistent double-digit revenue increases, the momentum has faded. In the first quarter, total revenues rose just 7.7% year over year. The Zacks Consensus Estimate depicts that this trend will persist, with mid-to-high single-digit growth expected for fiscal 2026 and 2027. How Rivals Stack Up Against Salesforce's Data Cloud Service Salesforce faces intensified competition from Microsoft Corporation MSFT and Snowflake Inc. SNOW in the data cloud space. Microsoft offers data services through its Azure Data platform. The company has already integrated the platform with its other productivity tools, including Power Platform, Dynamics 365 and Copilot AI, to enhance user experience and attract new clients. Many companies already use Microsoft's cloud and productivity software, making it easy to add its data services. Snowflake is another major competitor, known for its powerful cloud-based data warehouse. Unlike Salesforce, Snowflake focuses only on data, allowing companies to store, process and share large volumes easily. It also supports multiple clouds and has strong analytics tools. Salesforce's Price Performance, Valuation and Estimates Shares of Salesforce have plunged 29.1% year to date against the Zacks Computer – Software industry's growth of 20.8%. Image Source: Zacks Investment Research From a valuation standpoint, CRM trades at a forward price-to-earnings ratio of 19.77, significantly below the industry's average of 35.58. Image Source: Zacks Investment Research The Zacks Consensus Estimate for Salesforce's fiscal 2026 and 2027 earnings implies a year-over-year increase of approximately 10.8% and 11.5%, respectively. Estimates for fiscal 2026 and fiscal 2027 have been revised upward in the past 60 days. Image Source: Zacks Investment Research Salesforce currently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Microsoft Corporation (MSFT) : Free Stock Analysis Report Salesforce Inc. (CRM) : Free Stock Analysis Report Snowflake Inc. (SNOW) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
3 days ago
- Business
- Yahoo
ReNew Energy Global PLC (RNW) Q1 Earnings and Revenues Top Estimates
ReNew Energy Global PLC (RNW) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to break-even earnings per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +45.45%. A quarter ago, it was expected that this company would post earnings of $0.07 per share when it actually produced earnings of $0.1, delivering a surprise of +42.86%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. ReNew Energy Global, which belongs to the Zacks Alternative Energy - Other industry, posted revenues of $480 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 16.90%. This compares to year-ago revenues of $299 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. ReNew Energy Global shares have added about 10.1% since the beginning of the year versus the S&P 500's gain of 9.6%. What's Next for ReNew Energy Global? While ReNew Energy Global has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for ReNew Energy Global was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.22 on $465.9 million in revenues for the coming quarter and $0.26 on $1.59 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Alternative Energy - Other is currently in the bottom 33% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Golar LNG (GLNG), another stock in the broader Zacks Oils-Energy sector, has yet to report results for the quarter ended June 2025. The results are expected to be released on August 14. This operator of carriers for natural gas shipping is expected to post quarterly earnings of $0.29 per share in its upcoming report, which represents a year-over-year change of -31%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Golar LNG's revenues are expected to be $66.27 million, up 5.2% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ReNew Energy Global PLC (RNW) : Free Stock Analysis Report Golar LNG Limited (GLNG) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
